Anxiety disorders are a group of disorders that share symptoms like excessive fear and heightened stress (American Psychological Association [APA], 2022). It is important to note that fear and anxiety ...
The month of May is Mental Health Awareness Month, and an appropriate time to shine a spotlight on a mental health disorder that has been underserved and underacknowledged for too long. On May 4, ...
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain ...
Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional ...
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain ...
Hosted on MSN
MindMed launches phase 3 trial for anxiety treatment
The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...
Please provide your email address to receive an email when new articles are posted on . MM-120 demonstrated clinically and statistically significant reductions in anxiety compared with placebo at 12 ...
MindMed announced that the FDA has granted breakthrough designation to its MM120 program for the treatment of generalized anxiety disorder. MindMed also announced the pricing of an underwritten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback